Scarica l'app Stockscreener
2.46
2.77%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.53
Aprire:
$2.56
Volume 24 ore:
38,566
Relative Volume:
0.55
Capitalizzazione di mercato:
$24.71M
Reddito:
$1.15M
Utile/perdita netta:
$-46.90M
Rapporto P/E:
-0.4902
EPS:
-5.0182
Flusso di cassa netto:
$-42.37M
1 W Prestazione:
-9.23%
1M Prestazione:
-41.57%
6M Prestazione:
-72.14%
1 anno Prestazione:
-87.23%
Intervallo 1D:
$2.422
$2.56
Intervallo di 1 settimana:
$2.385
$2.78
Portata 52W:
$2.385
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
2.46 | 24.71M | 1.15M | -46.90M | -42.37M | -5.0182 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
Seres Therapeutics stock at EUR 2.28, USD 25.2 million market value - ad-hoc-news.de
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 - GlobeNewswire Inc.
A liquid experimental treatment reduced two bacteria up to 1,000-fold in preclinical tests. - Stock Titan
Seres Therapeutics to Present Preclinical Data for - GlobeNewswire
Analysts see USD 17 target for Seres Therapeutics stock - AD HOC NEWS
Seres Therapeutics leaves S&P Global BMI Index. Seres Therapeutics stock gains 1.16 percent - AD HOC NEWS
Seres Therapeutics (Nasdaq:MCRB)Stock Analysis - Simply Wall Street
Seres Therapeutics, Inc.(NasdaqGS: MCRB) dropped from S&P Global BMI Index - marketscreener.com
Seres Therapeutics stock holds steady as investors await next catalysts - AD HOC NEWS
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new hires get options on 4,200 Seres shares - stocktitan.net
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Microbiome Therapeutics Market Report 2026-2035 Featuring Profiles of Ferring Pharmaceuticals, Infant Bacterial Therapeutics, MaaT Pharma, Mikrobiomik, Seres Therapeutics, Vedanta Biosciences - Yahoo Finance
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - stocktitan.net
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Seres Therapeutics Inc. (MCRB) Peer Comparison – Compare with Others - Value Research
Seres Therapeutics Inc. (MCRB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Seres (MCRB) Earnings Report: The Available Earnings Metric Delivers a Beat; Post-Report: The Stock Ends Up 2.19%Profit Growth Outlook - vinanet.vn
MCRB|Seres Therapeutics Inc|Price:4.660|Chg%:+0.100 - TradingKey
Seres Therapeutics, Inc. SEC Filing (Aug 24, 2026) - Stock Titan
Seres Therapeutics reports positive SER-155 irEC study results - scanx.trade
Seres Therapeutics director Eric Shaff sells $1,196 in shares By Investing.com - Investing.com South Africa
Seres Therapeutics director Eric Shaff sells $1,196 in shares - Investing.com
Seres Therapeutics director Eric Shaff sells $1,196 in shares By Investing.com - Investing.com UK
Seres Therapeutics director Eric Shaff sells $1,196 in shares - Investing.com
Seres Therapeutics (NASDAQ: MCRB) COO sells 64 shares after 181 RSUs vest - Stock Titan
Seres Therapeutics (MCRB) director sale tied to RSU tax plan - Stock Titan
Seres Therapeutics, Inc. Revenue Breakdown – NASDAQ:MCRB - TradingView
Seres TherapeuticsMay Offer Up To $300 Million Of Securities - TradingView
Seres Therapeutics Files $300 Million Mixed Shelf - finance.yahoo.com
Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CCORF Maintains Seres Therapeutics(MCRB.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Seres Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Seres Therapeutics exits more Cambridge real estate early - The Business Journals
Seres Therapeutics Inc earnings beat by $2.77, revenue topped estimates - Investing.com
Seres Therapeutics Q2 Operating Income USD -2 - Moomoo
Seres Therapeutics, Inc. 2Q 2026: Revenue $0.736M, Net income $4.581M, EPS $0.47— 10-Q Summary - TradingView
Seres Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Seres Therapeutics (MCRB) Q2 Revenue Surpasses Expectations Amid Clinical Progress - GuruFocus
Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs - The Manila Times
Seres Therapeutics Q2 Net Income Reaches $4.6 Million - Quiver Quantitative
Seres Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Seres Therapeutics reports Q2 2026 net income of $4.6M, cash $15.6M, advances SER-155 clinical plans - TradingView
MCRB: Returned to profitability in Q2 2026, driven by VOWST sale gains and SER-155 trial success - TradingView
Q2 2026 financial results released as Seres Therapeutics advances business update - Traders Union
Seres Therapeutics Reports Second Quarter 2026 Financial - GlobeNewswire
Seres Therapeutics Reports Second Quarter 2026 Financial - globenewswire.com
Seres Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes - TipRanks
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Seres Therapeutics Inc Azioni (MCRB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shaff Eric D. | Director |
Aug 17 '26 |
Sale |
4.55 |
263 |
1,197 |
12,499 |
| Henn Matthew R | See Remarks |
Aug 17 '26 |
Sale |
4.55 |
81 |
369 |
7,995 |
| DesRosier Thomas | See Remarks |
Aug 17 '26 |
Sale |
4.55 |
82 |
373 |
8,117 |
| TERESA L YOUNG | Officer |
May 19 '26 |
Proposed Sale |
7.69 |
167 |
1,284 |
0 |
| Shaff Eric D. | Director |
May 18 '26 |
Sale |
7.53 |
259 |
1,950 |
12,040 |
| DesRosier Thomas | See Remarks |
May 18 '26 |
Sale |
7.53 |
79 |
595 |
7,954 |
| Henn Matthew R | See Remarks |
May 18 '26 |
Sale |
7.53 |
77 |
580 |
7,838 |
| Brady Kelly | See Remarks |
May 18 '26 |
Sale |
7.53 |
59 |
444 |
8,562 |
| TERESA L YOUNG | Officer |
Mar 17 '26 |
Proposed Sale |
9.12 |
8,553 |
77,967 |
0 |
| Shaff Eric D. | Director |
Feb 15 '26 |
Sale |
8.47 |
259 |
2,194 |
11,577 |
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):